Autres langues Lumos Pharma, Inc.

Actions

LUMO

US55028X1090

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
2,96 ^USD	-2,63%		+6,86%	-6,92%

07/03	Lumos Pharma, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
07/03	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	18/04
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	20/03
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	07/03
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	07/03
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	26/02
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	26/02
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	05/02
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	05/02
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	04/01
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	04/01
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	04/01
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	21/11
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	21/11
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November	20/11
North American Morning Briefing : Stock Futures -2-	13/11
Top Premarket Gainers	08/11
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	08/11
Lumos: Q3 Earnings Snapshot	08/11
Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints	08/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lumos Pharma, Inc.

Actions

LUMO

US55028X1090

Autres langues

Filtres